

## Influenza A(H3N2) egg-derived<sup>1</sup> candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)<sup>2</sup>

**27 February 2026 (Last updated 24 March 2026)**

### Candidate vaccine viruses antigenically like A/Darwin/1454/2025 (egg-derived) - Accession number (GISAID): EPI\_ISL\_20260622

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Darwin/1454/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia
	<b>IVR-283</b>	Classical	Seqirus	VIDRL, Australia
A/Darwin/1499/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia
	<b>IVR-284</b>	Classical	Seqirus	VIDRL, Australia
A/Darwin/1369/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia
A/Michigan/105/2025	Wild type virus		CDC, US	CDC, USA MHRA, UK
	<b>IVR-285</b>	Classical	Seqirus	MHRA, UK
	<b>SAN-049A</b>	Classical	Sanofi	Sanofi
A/Sichuan-Pingshan/323/2025	Wild type virus		CCDC	CCDC, China
	<b>CNIC-2601</b>	Classical		
A/Shanghai-Huangpu/12925/2025	Wild type virus			
	<b>CNIC-2602</b>	Classical		
	<b>CNIC-2602A</b>	Classical		

#### Institutes contact details for candidate vaccine virus orders/information:

CCDC: [fluchina@ivdc.chinacdc.cn](mailto:fluchina@ivdc.chinacdc.cn)

CDC: [cvvrequest@cdc.gov](mailto:cvvrequest@cdc.gov) (Subject: CVV request)

MHRA: [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

Sanofi: [Raymond.Schwartz@sanofi.com](mailto:Raymond.Schwartz@sanofi.com)

VIDRL: [enquiries@influenzacentre.org](mailto:enquiries@influenzacentre.org)

WHO CCs and ERLs: [http://www.who.int/influenza/gisrs\\_laboratory/collaborating\\_centres](http://www.who.int/influenza/gisrs_laboratory/collaborating_centres)

<sup>1</sup> For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

<sup>2</sup> <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

## Reference antigens (freeze-dried) – to be updated

Parent virus	Starting materials		Ref Ag Lot number	Unitage	Available from
	Candidate vaccine virus	Egg or cell		(µg HA/ml)	

## Sheep Antisera – to be updated

Purified HA from		Order Lot number	Available from
Parent virus	Egg or cell		

## WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

MHRA: [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

NIID: [flu-vaccine@nih.go.jp](mailto:flu-vaccine@nih.go.jp)

TGA: [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)

For reagents available from **CBER**, email [CBERShippingRequests@fda.hhs.gov](mailto:CBERShippingRequests@fda.hhs.gov).

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)